PHILADELPHIA, Dec. 23, 2019 /PRNewswire/ -- Lannett
Company, Inc. (NYSE: LCI) today announced that it has received
approvals from the U.S. Food and Drug Administration (FDA) of its
Abbreviated New Drug Applications (ANDAs) for Butalbital,
Acetaminophen and Caffeine (BAC) Capsules, USP, 50mg/300mg/40mg and
BAC Capsules, USP, 50 mg/325 mg/40 mg. The two dosage strengths of
BAC Capsules, have a combined estimated IQVIA market value of
approximately $68.6 million for the
12 months ending October 2019,
although actual generic market values are expected to be lower.
"We have commenced marketing both dosage strengths of our newly
approved BAC Capsules," said Tim
Crew, chief executive officer of Lannett. "Thus far in
fiscal 2020, we have launched about half a dozen products, among
them are Posaconazole, Prednisone and Cyproheptadine, and we expect
to launch as many as 12 products in the coming six months."
BAC Capsules, USP, 50mg/300mg/40mg and BAC Capsules, USP, 50
mg/325 mg/40 mg are the therapeutic equivalents of the reference
listed drugs BAC Capsules, USP, 50mg/300mg/40mg and BAC Capsules,
USP, 50 mg/325 mg/40 mg of Nexgen Pharma, Inc. and Mayne Pharma
Inc., respectively.
About Lannett Company, Inc.:
Lannett Company, founded
in 1942, develops, manufactures, packages, markets and distributes
generic pharmaceutical products for a wide range of medical
indications. For more information, visit the company's
website at www.lannett.com.
This news release contains certain statements of a
forward-looking nature relating to future events or future business
performance. Any such statement, including, but not limited
to, successfully commercializing Butalbital, Acetaminophen and
Caffeine Capsules, USP, 50mg/300mg/40mg and Butalbital,
Acetaminophen and Caffeine Capsules, USP, 50mg/325mg/40mg, and the
expected launch of as many as 12 products in the second half of
fiscal 2020, which includes several products in the next two
months, whether expressed or implied, is subject to market and
other conditions, and subject to risks and uncertainties which can
cause actual results to differ materially from those currently
anticipated due to a number of factors which include, but are not
limited to, the risk factors discussed in the Company's Form 10-K
and other documents filed with the SEC from time to time, including
the prospectus supplement related to the proposed offering to be
filed with the SEC. These forward-looking statements
represent the Company's judgment as of the date of this news
release. The Company disclaims any intent or obligation to
update these forward-looking statements.
Contact:
|
Robert
Jaffe
|
|
Robert Jaffe Co.,
LLC
|
|
(424)
288-4098
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lannett-receives-fda-approvals-for-two-dosage-strengths-of-butalbital-acetaminophen-and-caffeine-capsules-300978773.html
SOURCE Lannett Company, Inc.